422,446 Shares in RxSight, Inc. (NASDAQ:RXST) Acquired by DF Dent & Co. Inc.

DF Dent & Co. Inc. bought a new position in RxSight, Inc. (NASDAQ:RXST) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 422,446 shares of the company’s stock, valued at approximately $14,524,000. DF Dent & Co. Inc. owned 1.05% of RxSight at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Quarry LP increased its position in shares of RxSight by 82.3% during the 3rd quarter. Quarry LP now owns 638 shares of the company’s stock valued at $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd bought a new stake in RxSight during the third quarter valued at approximately $34,000. Private Trust Co. NA purchased a new stake in RxSight during the fourth quarter valued at approximately $34,000. Arcadia Investment Management Corp MI bought a new position in RxSight in the fourth quarter worth approximately $46,000. Finally, Harbor Investment Advisory LLC bought a new position in RxSight in the fourth quarter worth approximately $52,000. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

RxSight Stock Up 3.6 %

Shares of NASDAQ:RXST opened at $26.12 on Thursday. The firm has a fifty day simple moving average of $28.77 and a two-hundred day simple moving average of $38.46. RxSight, Inc. has a 52 week low of $20.00 and a 52 week high of $66.54. The stock has a market capitalization of $1.06 billion, a P/E ratio of -31.47 and a beta of 1.22.

RxSight (NASDAQ:RXST) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative net margin of 23.92% and a negative return on equity of 14.00%. On average, analysts expect that RxSight, Inc. will post -0.7 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Jesse Anderson Corley acquired 1,443 shares of RxSight stock in a transaction that occurred on Wednesday, January 15th. The shares were bought at an average cost of $31.18 per share, with a total value of $44,992.74. Following the transaction, the director now directly owns 1,443 shares of the company’s stock, valued at $44,992.74. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, Director Tamara Fountain sold 7,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now directly owns 24,793 shares of the company’s stock, valued at approximately $637,428.03. The trade was a 22.02 % decrease in their position. The disclosure for this sale can be found here. 9.36% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on RXST. Stifel Nicolaus decreased their target price on RxSight from $33.00 to $28.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. Needham & Company LLC reissued a “buy” rating and issued a $43.00 target price on shares of RxSight in a report on Wednesday, February 26th. Bank of America decreased their price target on RxSight from $60.00 to $36.00 and set a “buy” rating on the stock in a report on Friday, March 21st. UBS Group assumed coverage on shares of RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 target price on the stock. Finally, Wells Fargo & Company cut their target price on shares of RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 26th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $49.33.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.